Elke Langkopf

This inventor holds 72 USPTO granted patents and 23 published patent applications, plus 6 CIPO patents and 34 EPO patents, primarily in Pharmaceutical Compositions (CPC class C07D). Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co Kg, Boehringer Ingelheim Pharma Kg. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elke Langkopf. Retrieved from https://idiyas.com/inventor/elke-langkopf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 72 (Patent Applications = 23)

% Patents Active = 91.7

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 34 (Patent Applications = 34)

Average Co-Inventor Count = 5.1

ph-index = 32

Forward Citations = 2,373(Granted Patents)

Forward Citations (Not Self Cited) = 2,042(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Warthausen, DE (2002 - 2014)
Biberach an der Riss, DE (2012 - 2023)

Company Filing History:

49 out of 1,564

Boehringer Ingelheim International Gmbh

patents

15 out of 194

Boehringer Ingelheim Pharma Gmbh & Co Kg

patents

7 out of 149

Boehringer Ingelheim Pharma Kg

patents

4. 1 out of 1

Boehringer Ingelheim International Pharma Gmbh & Co. Kg

patent

Years Active: 2002-2025

Loading Chart...

Areas of Expertise:

Pharmaceutical Compositions

Azabenzimidazole Derivatives

Heteroaromatic Carboxamide

Xanthines

Quinazoline Derivatives

Cycloalkyl Compounds

Benzamides

Thienopyrimidines

Aryl Sulfonylaminomethylphosphonic Acids

Indanyloxydihydrobenzofuranylacetic Acids

Piperidine Derivatives

Diabetes Mellitus Treatments

72 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12479827 - Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors (2025-11-25),

2. 11760745 - Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors (2023-09-19),

3. 10695334 - Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors (2020-06-30),

4. 10501440 - Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors (2019-12-10),

5. 10307402 - Azabenzimidazole derivatives as agonists of the AMP-activated protein kinase (2019-06-04),

6. 10202383 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions (2019-02-12),

7. 10053471 - Azabenzimidazole derivatives (2018-08-21),

8. 10023574 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions (2018-07-17),

9. 9926308 - N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof (2018-03-27),

10. 9597310 - Indanyloxydihydrobenzofuranylacetic acids (2017-03-21),

11. 9556175 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions (2017-01-31),

12. 9492436 - Azabenzimidazole derivatives (2016-11-15),

13. 9422312 - Azabenzimidazole derivatives (2016-08-23),

14. 9321791 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions (2016-04-26),

15. 9108964 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions (2015-08-18),

Title: Elke Langkopf: A Trailblazer in Inventions

Introduction:

Elke Langkopf is a renowned inventor whose passion for innovation and relentless pursuit of excellence have solidified his reputation as a trailblazer in the world of inventions. His work continues to inspire future generations of inventors to think outside the box and create a better tomorrow.

Latest Patents:

Elke Langkopf's latest patents include groundbreaking inventions such as "Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors." These compounds have shown great potential for treating diseases influenced by the inhibition of plasma kallikrein, showcasing Langkopf's dedication to developing life-changing solutions.

Career Highlights:

Having accumulated an impressive portfolio of 71 patents, Elke Langkopf has made significant contributions to the field of pharmaceuticals and medical research. His innovative approach to problem-solving has led to the development of cutting-edge solutions that have the potential to revolutionize the way we approach healthcare.

Collaborations:

Throughout his career, Elke Langkopf has collaborated with industry giants such as Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharma GmbH & Co. KG. Working alongside esteemed coworkers like Frank Himmelsbach and Matthias Eckhardt, Langkopf has been able to leverage his expertise and creativity to push the boundaries of what is possible in the world of inventions.

Conclusion:

In conclusion, Elke Langkopf's commitment to innovation and his remarkable track record of inventive achievements position him as a true pioneer in the field of inventions. His work serves as a testament to the power of imagination and dedication in shaping a better future for generations to come.

Profile summary based on public USPTO records.